Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.

BACKGROUND: Efavirenz is a second-generation non-nucleoside inhibitor of HIV-1 reverse transcriptase (RT) that has recently been approved for use against HIV-1 infection. Compared with first-generation drugs such as nevirapine, efavirenz shows greater resilience to drug resistance mutations within...

Cijeli opis

Bibliografski detalji
Glavni autori: Ren, J, Milton, J, Weaver, K, Short, SA, Stuart, D, Stammers, D
Format: Journal article
Jezik:English
Izdano: 2000